Free Trial
ASX:PXS

Pharmaxis (PXS) Stock Price, News & Analysis

Pharmaxis logo

About Pharmaxis Stock (ASX:PXS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
721,139 shs
Average Volume
N/A
Market Capitalization
A$20.23 million
P/E Ratio
N/A
Dividend Yield
6.41%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharmaxis and its competitors with MarketBeat's FREE daily newsletter.

PXS Stock News Headlines

Canaccord Genuity Sticks to Their Buy Rating for Pharmaxis Ltd (SNT)
Pharmaxis Ltd Highlights Product Pipeline and Risks
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Syntara bolsters financial position with R&D tax incentive
FIVE at FIVE AU: ASX down 1.5% on Middle East fears; employment slows
Pharmaxis to focus on clinical-stage drug development
See More Headlines

PXS Stock Analysis - Frequently Asked Questions

Pharmaxis Ltd (ASX:PXS) posted its quarterly earnings results on Thursday, February, 14th. The company reported ($0.03) EPS for the quarter. Pharmaxis had a negative trailing twelve-month return on equity of 143.13% and a negative net margin of 161.24%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pharmaxis investors own include Atara Biotherapeutics (ATRA), CRISPR Therapeutics (CRSP), Acasti Pharma (ACST), American Woodmark (AMWD), Guardion Health Sciences (GHSI), Incannex Healthcare (IHL) and XPO (XPO).

Company Calendar

Last Earnings
2/14/2019
Today
7/10/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Transportation
Current Symbol
ASX:PXS
CIK
N/A
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
A($0.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
0.21
Net Income
-A$18.43 million
Net Margins
-161.24%
Pretax Margin
N/A
Return on Equity
-143.13%
Return on Assets
-48.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.21
Quick Ratio
14.73

Sales & Book Value

Annual Sales
A$11.89 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
1.32
Book Value
A$0.00 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
722,610,000
Free Float
N/A
Market Cap
A$20.23 million
Optionable
Not Optionable
Beta
0.64
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (ASX:PXS) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners